Eliciting B cell immunity against infectious diseases using nanovaccines

Singh, Ankur

doi:10.1038/s41565-020-00790-3

Cited by 133 publications

(140 citation statements)

References 69 publications

Supporting

Mentioning

137

Contrasting

Order By: Relevance

“…Antigen retention and presentation in lymph node follicles are prerequisites to the stimulation of robust B cell responses and GC reactions ( 35, 37, 89 ). Resident cells spatially rearrange antigens and present them to B cells.…”

Section: Resultsmentioning

confidence: 99%

Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants

Zhang

Paynter

Sou

et al. 2021

Preprint

View full text Add to dashboard Cite

Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are essential for combating the coronavirus disease 2019 (COVID-19) pandemic. Neutralizing antibody responses to the original Wuhan-Hu-1 strain that were generated during infection and vaccination showed lower effectiveness against variants of concern. Here, we demonstrated that mouse plasma induced by protein nanoparticles that present rationally designed S2GΔHR2 spikes can neutralize the B.1.1.7, B.1.351, and P.1 variants with comparable titers. The mechanism of nanoparticle vaccine-induced immunity was examined in mice for an I3-01v9 60-mer that presents 20 stabilized spikes. Compared with the soluble spike, this nanoparticle showed 6-fold longer retention, 4-fold greater presentation on follicular dendritic cell dendrites, and 5-fold higher germinal center reactions in lymph node follicles. Intact nanoparticles in lymph node tissues were visualized by transmission electron microscopy. In conclusion, spike-presenting protein nanoparticles that induce robust long-lived germinal centers may provide a vaccine solution for emerging SARS-CoV-2 variants.

show abstract

Section: Resultsmentioning

confidence: 99%

Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants

Zhang

Paynter

Sou

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…7b-f). The antigenic hypervariability 9,17 and microbiome heterogeneity 18,19 of the bacterial infection impose the current bacterial vaccines with constricted breadth of bacteria-speci c immune memory responses by both B cell and T cell. Thus, we sought to evaluate whether HMMP could elicit effective immune recall response or not by using ow cytometry analysis (Fig.…”

Section: Hmmp-conferred Long-lasting Protective Immunity Against Bactmentioning

confidence: 99%

Biomimetic nanomedicine-triggered in situ vaccination for innate and adaptive immunity activations for bacterial osteomyelitis treatment

Lin

Yang

Min

et al. 2021

Preprint

View full text Add to dashboard Cite

The development of bacterial vaccines for inducing immunoresponse against infectious diseases such as osteomyelitis is of great significance and importance. However, the responsiveness of bacterial immunotherapy remains far from being satisfactory largely due to the erratic antigen epitopes of bacteria. Herein, we report an in situ vaccination strategy for the immunotherapy of bacterial infection based on an osteomyelitis model using a biomimetic nanomedicine named as HMMP, which was constructed by engineering PpIX-encapsulated hollow MnOx with a hybrid membrane exfoliated from both macrophage and tumor cell lines. The as-established HMMP features a burst bacterial antigen release as the in situ vaccine by the augmented sonodynamic treatment, and the resultant priming of antigen presenting cells for the following activations of both cellular and humoral adaptive immunities against bacterial infections. This treatment regimen not only triggers initial bacterial regression in established osteomyelitis model, also simultaneously generate robust systemic antibacterial immunity against poorly immunogenic secondary osteomyelitis in the contralateral knee as well, and additionally, confers long-lasting bacteria-specific immune memory responses to prevent infection relapse. Thus, our study provides a proof of concept of in situ vaccination for the activation of both innate and adaptive antibacterial immune responses, providing an individual-independent bacterial immunotherapy.

show abstract

“…The importance of GCs in infection and vaccine responses has been demonstrated in numerous studies (3)(4)(5). However, the molecular nature of the GC incurs risk.…”

Section: Introductionmentioning

confidence: 99%

Compartments and Connections Within the Germinal Center

Kennedy

Clark

2021

Front. Immunol.

View full text Add to dashboard Cite

Protective high affinity antibody responses emerge through an orchestrated developmental process that occurs in germinal centers (GCs). While GCs have been appreciated since 1930, a wealth of recent progress provides new insights into the molecular and cellular dynamics governing humoral immunity. In this review, we highlight advances that demonstrate that fundamental GC B cell function, selection, proliferation and SHM occur within distinct cell states. The resulting new model provides new opportunities to understand the evolution of immunity in infectious, autoimmune and neoplastic diseases.

show abstract

Eliciting B cell immunity against infectious diseases using nanovaccines

Cited by 133 publications

References 69 publications

Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants

Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants

Biomimetic nanomedicine-triggered in situ vaccination for innate and adaptive immunity activations for bacterial osteomyelitis treatment

Compartments and Connections Within the Germinal Center

Contact Info

Product

Resources

About